Solid-in-oil nanodispersions for transcutaneous immunotherapy of Japanese cedar pollinosis

4Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

Abstract

Japanese cedar pollinosis (JCP) is a common affliction caused by an allergic reaction to cedar pollen and is considered a disease of national importance in Japan. Antigen-specific immunotherapy (AIT) is the only available curative treatment for JCP. However, low compliance and persistence have been reported among patients subcutaneously or sublingually administered AIT comprising a conventional antigen derived from a pollen extract. To address these issues, many research studies have focused on developing a safer, simpler, and more effective AIT for JCP. Here, we review the novel antigens that have been developed for JCP AIT, discuss their different administration routes, and present the effects of anti-allergy treatment. Then, we describe a new form of AIT called transcutaneous immunotherapy (TCIT) and its solid-in-oil (S/O) nanodispersion formulation, which is a promising antigen delivery system. Finally, we discuss the applications of S/O nanodispersions for JCP TCIT. In this context, we predict that TCIT delivery by using a S/O nanodispersion loaded with novel antigens may offer an easier, safer, and more effective treatment option for JCP patients.

Cite

CITATION STYLE

APA

Kong, Q., Kitaoka, M., Wakabayashi, R., Tahara, Y., Kamiya, N., & Goto, M. (2020, March 1). Solid-in-oil nanodispersions for transcutaneous immunotherapy of Japanese cedar pollinosis. Pharmaceutics. MDPI AG. https://doi.org/10.3390/pharmaceutics12030240

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free